Ethical Considerations in Conducting Clinical Trials
International Journal of Medical Toxicology and Forensic Medicine,
Vol. 11 No. 4 (2021),
17 November 2021
,
Page 34863
https://doi.org/10.32598/ijmtfm.v11i4.34863
Abstract
Background: Clinical trials are the golden key in medical science research with human participants. They have always been considered interesting topics by researchers and scientists working in this field. However, the samples are “human participants,” so the research should be carefully conducted.
Methods: In the present study, the published articles on the ethical challenges of conducting clinical trials were evaluated between 2010 and 2019 in Google Scholar, PubMed, and Scopus. The English search keywords were “clinical trial,” with at least one of the phrases of “ethical consideration” or “standard”.
Results: In this article, we examined the ethical requirements and considerations in these research studies in four stages: research design and question, proposal review and approval, supervision and implementation, and publication of the results. We have examined them using relevant articles published between 2010 and 2019 and identified important and prominent issues or neglected ones.
Conclusion: During this study, it was found that the “research design and question” stage was the most discussed and challenging stage, and the authors’ sensitivity about it has been more than the other three stages. On the other hand, the “results publishing” stage has been considered less sensitive with the least number of references in articles.
- Clinical trials
- Research
- Equipoise
How to Cite
References
World Health Organization. International clinical trials registry platform [Internet].2021 [Updated 2021 February 8]. Availble from: https://www.who.int/clinical-trials-registry-platform
Morgan GA, Harmon RJ. Research questions and hypotheses. J Am Acad Child Adolesc Psychiatry. 2000; 39(2):261-3. [DOI:10.1097/00004583-200002000-00028] [PMID]
van der Graaf R, van Delden JJ. Equipoise should be amended, not abandoned. Clin Trials. 2011; 8(4):408-16. [DOI:10.1177/1740774511409600] [PMID]
Friedman LM, Furberg CD, DeMets DL, Reboussin DM, Granger CB. what is the question? In: Friedman LM, Furberg CD, DeMets DL, Reboussin DM, Granger CB, editors. Fundamentals of clinical trials. Cham: Springer; 2015. [DOI:10.1007/978-3-319-18539-2_3]
Okonta PI. Ethics of clinical trials in Nigeria. Niger Med J. 2014; 55(3):188-94. [DOI:10.4103/0300-1652.132035] [PMID] [PMCID]
Hey SP, Truog RD. The question of clinical equipoise and patients’ best interests. AMA J Ethics. 2015; 17(12):1108-15. [DOI:10.1001/journalofethics.2015.17.12.ecas1-1512] [PMID]
Pillamarapu M, Mohan A, Saberwal G. An analysis of deficiencies in the data of interventional drug trials registered with Clinical Trials Registry - India. Trials. 2019; 20(1):535 [DOI:10.1186/s13063-019-3592-0] [PMID] [PMCID]
Karlberg J, Speers M. Reviewing clinical trials: a guide for the ethics committee: Hong Kong; 2010.p.23-45
Bothwell LE, Kesselheim AS. The real-world ethics of adaptive-design Clinical Trials. Hastings Cent Rep. 2017; 47(6):27-37. [DOI:10.1002/hast.783] [PMID]
Sim J. Outcome-adaptive randomization in clinical trials: Issues of participant welfare and autonomy. Theor Med Bioeth. 2019; 40(2):83-101. [DOI:10.1007/s11017-019-09481-0] [PMID] [PMCID]
Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, et al. Adaptive designs in clinical trials: Why use them, and how to run and report them. BMC Med. 2018; 16(1):29. [DOI:10.1186/s12916-018-1017-7] [PMID] [PMCID]
Rosemann A. Alter-standardizing Clinical Trials: The gold standard in the crossfire. Sci Cult. 2019; 28(2):125-48. [DOI:10.1080/09505431.2019.1606190]
Chen SC, Kim SY. A framework for analysis of research risks and benefits to participants in standard of care pragmatic clinical trials. Clin Trials. 2016; 13(6):605-11. [DOI:10.1177/1740774516656945] [PMID] [PMCID]
Mentz RJ, Hernandez AF, Berdan LG, Rorick T, O’Brien EC, Ibarra JC, et al. Good clinical practice guidance and pragmatic Clinical Trials: Balancing the best of both worlds. Circulation. 2016; 133(9):872-80. [DOI:10.1161/CIRCULATIONAHA.115.019902] [PMID] [PMCID]
Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: Defining standard protocol items for clinical trials. Ann Intern Med. 2013; 158(3):200-7. [DOI:10.7326/0003-4819-158-3-201302050-00583] [PMID] [PMCID]
Kyte D, Duffy H, Fletcher B, Gheorghe A, Mercieca-Bebber R, King M, et al. Systematic evaluation of the patient-reported outcome (PRO) content of clinical trial protocols. PLoS One. 2014; 9(10):e110229. [DOI:10.1371/journal.pone.0110229] [PMID] [PMCID]
Hedgecoe A. A deviation from standard design? Clinical trials, research ethics committees, and the regulatory co-construction of organizational deviance. Soc Stud Sci. 2014; 44(1):59-81. [DOI:10.1177/0306312713506141] [PMID]
Clark T, Berger U, Mansmann U. Sample size determinations in original research protocols for randomised clinical trials submitted to UK research ethics committees: Review. BMJ. 2013; 346:f1135. [DOI:10.1136/bmj.f1135] [PMID] [PMCID]
Sajdak R, Trembath L, Thomas KS. The importance of standard operating procedures in clinical trials. J Nucl Med Technol. 2013; 41(3):231-3. [DOI:10.2967/jnmt.113.121467] [PMID]
Day S, Jonker AH, Lau LPL, Hilgers RD, Irony I, Larsson K, et al. Recommendations for the design of small population clinical trials. Orphanet J Rare Dis. 2018; 13(1):195. [DOI:10.1186/s13023-018-0931-2] [PMID] [PMCID]
Haynes R, Bowman L, Rahimi K, Armitage J. How the NHS research governance procedures could be modified to greatly strengthen clinical research. Clin Med (Lond). 2010; 10(2):127-9. [DOI:10.7861/clinmedicine.10-2-127] [PMID] [PMCID]
Jesani A, Srinivasan S. New Drugs and Clinical Trials Rules, 2019: The market trumps ethics and participant rights. Indian J Med Ethics. 2019; 4(2):89-91. [PMID]
Maeda K, Katashima R, Ishizawa K, Yanagawa H. Japanese physicians’ views on drug post-marketing surveillance. J Clin Med Res. 2015; 7(12):956-60. [PMID] [PMCID]
Russ H, Busta S, Jost B, Bethke TD. Evaluation of clinical trials by Ethics Committees in Germany--results and a comparison of two surveys performed among members of the German Association of Research-Based Pharmaceutical Companies (vfa). Ger Med Sci. 2015; 13:Doc02. [PMID]
Ilbars H, Bebitoglu BT. How to get ethics committee approval for clinical trials in Turkey? North Clin Istanb. 2018; 5(4):379-86. [DOI:10.14744/nci.2018.68815] [PMID] [PMCID]
Nardini C. The ethics of clinical trials. Ecancermedicalscience. 2014; (8):387. [PMID]
Desai M. Ethics committee: Critical issues and challenges. Indian J Pharmacol. 2012; 44(6):663-4. [DOI:10.4103/0253-7613.103233] [PMID] [PMCID]
Thatte UM, Marathe PA. Ethics Committees in India: Past, present and future. Perspect Clin Res. 2017; 8(1):22-30. [DOI:10.4103/2229-3485.198549] [PMID] [PMCID]
Liu Y, LI X. The Function of Medical Ethics Professionals in Ethical Review of Clinical Trials Involving Human Subjects. Chinese Med Ethic. 2016:285-7. https://pesquisa.bvsalud.org/portal/resource/pt/wpr-491346
Trung LQ, Morra ME, Truong ND, Turk T, Elshafie A, Foly A, et al. A systematic review finds underreporting of ethics approval, informed consent, and incentives in clinical trials. J Clin Epidemiol. 2017; 91:80-6. [DOI:10.1016/j.jclinepi.2017.08.007] [PMID]
Li R, Barnes M, Aldinger CE, Bierer BE. Global clinical trials: Ethics, harmonization and commitments to transparency. Harv Public Health Rev. 2015; 6, 1-7. https://www.jstor.org/stable/48503032
Vollmer SH, Howard G. Statistical power, the Belmont report, and the ethics of clinical trials. Sci Eng Ethics. 2010; 16(4):675-91. [DOI:10.1007/s11948-010-9244-0] [PMID]
Lie RK, Chan FKL, Grady C, Ng VH, Wendler D. Comparative effectiveness research: What to do when experts disagree about risks. BMC Med Ethics. 2017; 18(1):42. [DOI:10.1186/s12910-017-0202-0] [PMID] [PMCID]
Modi N, Vohra J, Preston J, Elliott C, Van’t Hoff W, Coad J, et al. Guidance on clinical research involving infants, children and young people: An update for researchers and research ethics committees. Arch Dis Child. 2014; 99(10):887-91. [DOI:10.1136/archdischild-2014-306444] [PMID]
Strech D, Sievers S, Märschenz S, Riedel N, Wieschowski S, Meerpohl J, et al. Tracking the timely dissemination of clinical studies. Characteristics and impact of 10 tracking variables. F1000Res. 2018; 7:1863. [DOI:10.12688/f1000research.17022.1] [PMID] [PMCID]
Djulbegovic B, Hozo I. When is it rational to participate in a clinical trial? A game theory approach incorporating trust, regret and guilt. BMC Med Res Methodol. 2012; 12:85. [DOI:10.1186/1471-2288-12-85] [PMID] [PMCID]
Speich B, Schur N, Gryaznov D, von Niederhäusern B, Hemkens LG, Schandelmaier S, et al. Resource use, costs, and approval times for planning and preparing a randomized clinical trial before and after the implementation of the new Swiss human research legislation. PLoS One. 2019; 14(1):e0210669. [DOI:10.1371/journal.pone.0210669] [PMID] [PMCID]
Biggs JS, Marchesi A. Rebuilding a Research Ethics Committee. J Res Adm. 2013; 44(1):62-74. https://eric.ed.gov/?id=EJ1013313
Tabarrai M, Qaraaty M, Aliasl J. The challenges of clinical researches in Iranian Traditional Medicine (ITM). Iran J Med Sci. 2016; 41(3 Suppl):S60. [PMID]
Li EC, Du P, Ji KZ, Wang Z. Chinese ethics review system and Chinese medicine ethical review: Past, present, and future. Chin J Integr Med. 2011; 17(11):867-72. [DOI:10.1007/s11655-011-0898-5] [PMID]
Kaufman KR. Ethical considerations in placebo-controlled randomised clinical trials. BJPsych Open. 2015; 1(1):e3-e4. [DOI:10.1192/bjpo.bp.115.000919] [PMID] [PMCID]
Shepherd V. Research involving adults lacking capacity to consent: The impact of research regulation on ‘evidence biased’ medicine. BMC Med Ethics. 2016; 17(1):55. [DOI:10.1186/s12910-016-0138-9] [PMID] [PMCID]
Jadhav M, Bhatt A. Ethics in clinical research in India: A survey of clinical research professionals’ perceptions. Perspect Clin Res. 2013; 4(1):4-8. [DOI:10.4103/2229-3485.106368] [PMID] [PMCID]
Samadi A, Asghari F. Readability of informed consent forms in clinical trials conducted in a skin research center. J Med Ethics Hist Med. 2016; 9:7. [PMID]
Viergever RF, Li K. Trends in global clinical trial registration: An analysis of numbers of registered clinical trials in different parts of the world from 2004 to 2013. BMJ Open. 2015; 5(9):e008932. [DOI:10.1136/bmjopen-2015-008932] [PMID] [PMCID]
Viergever R, Ghersi D. The quality of registration of clinical trials. PLoS One. 2011; 6(2):e14701. [DOI:10.1371/journal.pone.0014701] [PMID] [PMCID]
Thorogood A, Knoppers BM. Can research ethics committees enable clinical trial data sharing? Ethics Med Public Health. 2017; 3(1):56-63. [DOI:10.1016/j.jemep.2017.02.010]
Saenz C, Reveiz L, Tisdale JF. Public titles of clinical trials should have ethics review. J Clin Epidemiol. 2015; 68(9):1105-7. [DOI:10.1016/j.jclinepi.2014.05.016] [PMID]
Fakhri F, Eybpoosh S, Solaymani Dodaran M. [Characteristics of clinical trials in Iran: A sample of 5000 trials registered in Iranian Registry of Clinical Trials (IRCT) (Persian)]. Iran J Epidemiol. 2019; 15(1):8-19. http://irje.tums.ac.ir/article-1-6277-en.html
Gøtzsche PC. Why we need easy access to all data from all clinical trials and how to accomplish it. Trials. 2011; 12:249. [DOI:10.1186/1745-6215-12-249] [PMID] [PMCID]
Xuemei L, Youping L, Shangqi S, Senlin Y, Williams S. Ethical review reporting of Chinese trials records in WHO primary registries. J Med Ethics. 2011; 37(3):144-8. [DOI:10.1136/jme.2010.036558] [PMID]
Denneny C, Bourne S, Kolstoe SE. Registration audit of clinical trials given a favourable opinion by UK research ethics committees. BMJ Open. 2019; 9(2):e026840. [DOI:10.1136/bmjopen-2018-026840] [PMID] [PMCID]
Dyer C. UK clinical trials must be registered to win ethics committee approval. BMJ. 2013; (347):f5614 [DOI:10.1136/bmj.f5614] [PMID]
Liu X, Li Y, Yin S, Song S. Result publication of Chinese trials in World Health Organization primary registries. PLoS One. 2010; 5(9):e12676. [DOI:10.1371/journal.pone.0012676] [PMID] [PMCID]
Gillies K, Elwyn G, Cook J. Making a decision about trial participation: The feasibility of measuring deliberation during the informed consent process for clinical trials. Trials. 2014; 15(1):307. [DOI:10.1186/1745-6215-15-307] [PMID] [PMCID]
Watson SI, Dixon-Woods M, Lilford RJ. Randomised evaluation of government health programmes does present a challenge to standard research ethics frameworks. J Med Ethics. 2020; 46(1):34-5. [DOI:10.1136/medethics-2019-106003] [PMID]
Stanev R. Quantitative framework for retrospective assessment of interim decisions in clinical trials. Med Decis Making. 2016; 36(8):999-1010. [DOI:10.1177/0272989X16655346] [PMID] [PMCID]
van der Tweel Iv, Roes KC. [When is enough evidence available?; interim analyses in clinical trials (Dutch)]. Ned Tijdschr Geneeskd. 2013; 157(12):A5660. [PMID]
Laage T, Loewy JW, Menon S, Miller ER, Pulkstenis E, Kan-Dobrosky N, et al. Ethical considerations in adaptive design clinical trials. Ther Innov Regul Sci. 2017; 51(2):190-9. [DOI:10.1177/2168479016667766] [PMID]
Freidlin B, Othus M, Korn EL. Information time scales for interim analyses of randomized clinical trials. Clin Trials. 2016; 13(4):391-9. [DOI:10.1177/1740774516644752] [PMID]
Goldacre B, Drysdale H, Dale A, Milosevic I, Slade E, Hartley P, et al. COMPare: A prospective cohort study correcting and monitoring 58 misreported trials in real time. Trials. 2019; 20(1):118. [DOI:10.1186/s13063-019-3173-2] [PMID] [PMCID]
Miller JE, Korn D, Ross JS. Clinical trial registration, reporting, publication and FDAAA compliance: A cross-sectional analysis and ranking of new drugs approved by the FDA in 2012. BMJ Open. 2015; 5(11):e009758. [DOI:10.1136/bmjopen-2015-009758] [PMID] [PMCID]
Bashir R, Dunn AG. Systematic review protocol assessing the processes for linking clinical trial registries and their published results. BMJ Open. 2016; 6(10):e013048. [DOI:10.1136/bmjopen-2016-013048] [PMID] [PMCID]
Butcher NJ, Monsour A, Mew EJ, Szatmari P, Pierro A, Kelly LE, et al. Improving outcome reporting in clinical trial reports and protocols: Study protocol for the Instrument for reporting Planned Endpoints in Clinical Trials (InsPECT). Trials. 2019; 20(1):161. [DOI:10.1186/s13063-019-3248-0] [PMID] [PMCID]
Strech D, Littmann J. The contribution and attitudes of research ethics committees to complete registration and non-selective reporting of clinical trials: A European survey. Res Ethics. 2016; 12(3):123-36. [DOI:10.1177/1747016115626497]
Brassington I. The ethics of reporting all the results of clinical trials. Br Med Bull. 2017; 121(1):19-29. [DOI:10.1093/bmb/ldw058] [PMID]
Marusic A, Wager E, Utrobicic A, Rothstein HR, Sambunjak D. Interventions to prevent misconduct and promote integrity in research and publication. Cochrane Database Syst Rev. 2016; 4(4):MR000038. [DOI:10.1002/14651858.MR000038.pub2] [PMID] [PMCID]
Larijani MB, Zahedi F, Malek-Afzali H. [History and activities of medical ethics in Iran (Persian)]. J Diabetes Metab Disord. 2004; ):13-24. https://www.sid.ir/en/journal/ViewPaper.aspx?ID=26579
Mohamadi A, Asghari F, Rashidian A. Continuing review of ethics in clinical trials: A surveillance study in Iran. J Med Ethics Hist Med. 2014; 7:22. [PMID]
Ghasemzadeh N, Nikravan Fard N, Rahimi Rad MH, Mousavipour S, Faramarzi Razini F. [A survey on the rate of observance of research ethics in approved proposals at Urmia University of Medical Sciences (2003 - 2008) (Persian)]. J Med Ethics Hist Med. 2013; 6(2):67-85. https://www.sid.ir/en/journal/ViewPaper.aspx?ID=318343
- Abstract Viewed: 373 times
- PDF Downloaded: 313 times